Catalog No.A2016 Synonyms: SHR-1210
For research use only. Not for use in humans.
Camrelizumab is a humanized anti-PD-1 IgG4 antibody that blocks the binding of PD-L1 and PD-L2 to PD-1 with immune checkpoint inhibitory and antineoplastic activities.
Choose Selective PD-1/PD-L1 Inhibitors
|Description||Camrelizumab is a humanized anti-PD-1 IgG4 antibody that blocks the binding of PD-L1 and PD-L2 to PD-1 with immune checkpoint inhibitory and antineoplastic activities.|
|Formulation||PBS buffer, pH 7.2|
|Storage||Store at -80°C and avoid freeze-thaw cycles.|
Clinical Trial Information
|NCT Number||Recruitment||Conditions||Sponsor/Collaborators||Start Date||Phases|
|NCT03557411||Recruiting||Non-Small-Cell Lung Cancer||Shandong Cancer Hospital and Institute|Jiangsu HengRui Medicine Co. Ltd.||July 9 2018||Phase 2|
|NCT03155425||Recruiting||Hodgkin Lymphoma Adult||Jiangsu HengRui Medicine Co. Ltd.||June 9 2017||Phase 2|
|NCT03085069||Recruiting||Lung Neoplasms|Carcinoma Non-Small-Cell Lung|Respiratory Tract Neoplasms Nec|Lung Disease|Respiratory Tract Disease|Neoplasm Bronchial|Carcinoma Bronchogenic||Jiangsu HengRui Medicine Co. Ltd.||June 9 2017||Phase 2|
|NCT03463876||Recruiting||Hepatocellular Carcinoma||Jiangsu HengRui Medicine Co. Ltd.||February 5 2018||Phase 2|
|NCT03417895||Not yet recruiting||Small-cell Lung Cancer||Jiangsu HengRui Medicine Co. Ltd.||February 5 2018||Phase 2|
|NCT03603756||Recruiting||Esophageal Squamous Cell Carcinoma||Chinese Academy of Medical Sciences||July 31 2018||Phase 2|
If you have any other enquiries, please leave a message.